| Literature DB >> 23533491 |
Ju Yuan1, Yu Lu, Saifuding Abula, Yuanliang Hu, Jiaguo Liu, Yunpeng Fan, Xiaojuan Zhao, Deyun Wang, Xu Liu, Cui Liu.
Abstract
The aim of this study is to prepare propolis flavonoids liposome (PFL) and optimize the preparation condition and to investigate further whether liposome could promote the immunoenhancement activity of propolis flavonoids (PF). PFL was prepared with ethanol injection method, and the preparation conditions of PFL were optimized with response surface methodology (RSM). Moreover, the immunoenhancement activity of PFL and PF in vitro was determined. The result showed that the optimal preparation conditions for PFL by response surface methodology were as follows: ratio of lipid to drug (w/w) 9.6 : 1, ratio of soybean phospholipid to cholesterol (w/w) 8.5 : 1, and speed of injection 0.8 mL·min(-1). Under these conditions, the experimental encapsulation efficiency of PFL was 91.67 ± 0.21%, which was close to the predicted value. Therefore, the optimized preparation condition is very reliable. Moreover, the results indicated that PFL could not only significantly promote lymphocytes proliferation singly or synergistically with PHA, but also increase expression level of IL-2 and IFN-γ mRNA. These indicated that liposome could significantly improve the immunoenhancement activity of PF. PFL demonstrates the significant immunoenhancement activity, which provides the theoretical basis for the further experiment in vivo.Entities:
Year: 2013 PMID: 23533491 PMCID: PMC3603480 DOI: 10.1155/2013/505703
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Factors and levels of Box-Behnnken experimental design.
| Factors | Code | Range and levels | ||
|---|---|---|---|---|
| −1 | 0 | 1 | ||
| A ( ratio of lipid to drug, w/w) |
| 5 : 1 | 10 : 1 | 15 : 1 |
| B (ratio of soybean phospholipid |
| 6 : 1 | 8 : 1 | 10 : 1 |
| C (speed of injection, mL·min−1) |
| 0.3 | 0.6 | 1.2 |
Response surface Box-Behnken design and experimental encapsulation efficiency (%).
| Number | Levels of independent factors | Response EE (%) | |||
|---|---|---|---|---|---|
|
|
|
| Practical acquired EE | Predicted acquired EE | |
| 1 | 5 : 1 | 8 : 1 | 0.3 | 76.00 | 74.99 |
| 2 | 5 : 1 | 10 : 1 | 0.6 | 82.60 | 82.88 |
| 3 | 15 : 1 | 6 : 1 | 0.6 | 76.90 | 76.62 |
| 4 | 15 : 1 | 8 : 1 | 1.2 | 72.10 | 73.11 |
| 5 | 10 : 1 | 10 : 1 | 1.2 | 82.04 | 81.41 |
| 6 | 15 : 1 | 10 : 1 | 0.6 | 80.15 | 79.78 |
| 7 | 10 : 1 | 6 : 1 | 0.3 | 76.40 | 77.03 |
| 8 | 15 : 1 | 8 : 1 | 0.3 | 78.25 | 77.89 |
| 9 | 10 : 1 | 6 : 1 | 1.2 | 77.00 | 76.27 |
| 10 | 10 : 1 | 8 : 1 | 0.6 | 92.60 | 91.30 |
| 11 | 10 : 1 | 8 : 1 | 0.6 | 90.78 | 91.30 |
| 12 | 10 : 1 | 10 : 1 | 0.3 | 80.02 | 80.75 |
| 13 | 10 : 1 | 8 : 1 | 0.6 | 91.00 | 91.30 |
| 14 | 10 : 1 | 8 : 1 | 0.6 | 91.54 | 91.30 |
| 15 | 5 : 1 | 6 : 1 | 0.6 | 76.80 | 77.17 |
| 16 | 10 : 1 | 8 : 1 | 0.6 | 90.58 | 91.30 |
| 17 | 5 : 1 | 8 : 1 | 1.2 | 79.30 | 79.66 |
Estimated regression model of relationship between response variables (EE) and independent variables (X 1, X 2, and X 3).
| Source | Sun of squares | df | Mean square |
|
|
|---|---|---|---|---|---|
| Model | 700.32 | 9 | 77.81 | 75.33 | <0.0001 |
| A | 6.66 | 1 | 6.66 | 6.45 | 0.0387 |
| B | 39.21 | 1 | 39.21 | 37.96 | 0.0005 |
| C | 6.612 × 10−3 | 1 | 6.612 × 10−3 | 6.402 × 10−3 | 0.9385 |
| AB | 1.63 | 1 | 1.63 | 1.57 | 0.2499 |
| AC | 22.33 | 1 | 22.33 | 21.61 | 0.0023 |
| BC | 0.50 | 1 | 0.50 | 0.49 | 0.5073 |
|
| 225.61 | 1 | 225.61 | 218.42 | <0.0001 |
|
| 99.76 | 1 | 99.76 | 96.58 | <0.0001 |
|
| 241.12 | 1 | 241.12 | 233.44 | <0.0001 |
| Residual | 7.23 | 7 | 1.03 | ||
| Lack of fit | 4.60 | 3 | 1.53 | 2.34 | 0.2150 |
| Pure error | 2.63 | 4 | 0.66 | ||
| Cor total | 707.55 | 16 | |||
|
|
| ||||
Predicted and experimental values of the responses at optimum conditions.
| Ratio of lipid to drug (w/w) | Ratio of soybean phospholipid to cholesterol (w/w) | Speed of injection/(mL·min−1) | EE (%) | |
|---|---|---|---|---|
| Optimum conditions | 9.630 : 1 | 8.470 : 1 | 0.760 | 91.59 |
| Modified conditions | 9.6 : 1 | 8.5 : 1 | 0.8 | 91.67 ± 0.21 |
Figure 1Changes of T lymphocyte proliferation in single stimulation with drugs (A 570 values). a–cBars in the same day without the same superscripts differ significantly (P < 0.05).
Figure 2Changes of T lymphocyte proliferation in synergistical stimulation of drugs with PHA (A 570 values). a–dBars in the same day without the same superscripts differ significantly (P < 0.05).
Figure 3Effect of PFL on expression level of IL-2 mRNA. a–dBars in the same day without the same superscripts differ significantly (P < 0.05). *means significantly different between two groups (P < 0.05). **means significantly different between two groups (P < 0.01).
Figure 4Effect of PFL on expression level of IFN-γ mRNA. a–dBars in the same day without the same superscripts differ significantly (P < 0.05). *means significantly different between two groups (P < 0.05). **means significantly different between two groups (P < 0.01).